We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The Effect of Rosuvastatin on Markers of Immune Activation in Treatment-Naive Human Immunodeficiency Virus-Patients.
- Authors
Weijma, Robyn G. M.; Vos, Eric R. A.; Oever, Jaap Ten; Van Schilfgaarde, Muriel; Dijksman, Lea M.; Van Der Ven, André; Van Den Berk, Guido E. L.; Brinkman, Kees; Frissen, Jos P. H. J.; Leyte, Anja; Schouten, Ineke W. E. M.; Netea, Mihai G.; Blok, Willem L.
- Abstract
Background. Immune activation has been implicated in the excess mortality in human immunodeficiency virus (HIV)-infected patients, due to cardiovascular diseases and malignancies. Statins may modulate this immune activation. We assessed the capacity of rosuvastatin to mitigate immune activation in treatment-naive HIV-infected patients. Methods. In a randomized double-blind placebo-controlled crossover study, we explored the effects of 8 weeks of rosuvastatin 20 mg in treatment-naive male HIV-infected patients (n = 28) on immune activation markers: neopterin, soluble Toll-like receptor (TLR)2, sTLR4, interleukin (IL)-6, IL-1Ra, IL-18, D-dimer, highly sensitive C-reactive protein, and CD38 and/or human leukocyte antigen-DR expression on T cells. Baseline data were compared with healthy male controls (n = 10). Furthermore, the effects of rosuvastatin on HIV-1 RNA, CD4/CD8 T-cell count, and low-density lipoprotein cholesterol were examined and side effects were registered. Results. T-cell activation levels were higher in patients than in controls. Patients had higher levels of circulating IL-18, sTLR2, and neopterin (all P< .01). Twenty patients completed the study. Rosuvastatin increased the CD4/CD8 T-cell ratio (P = .02). No effect on other markers was found. Conclusions. Patients infected with HIV had higher levels of circulating neopterin, IL-18, sTLR2, and T-cell activation markers. Rosuvastatin had a small but significant positive effect on CD4/CD8 T-cell ratio, but no influence on other markers of T-cell activation and innate immunity was identified (The Netherlands National Trial Register [NTR] NTR 2349, http://www. trialregister.nl/trialreg/index.asp).
- Subjects
ROSUVASTATIN; PATIENTS
- Publication
Open Forum Infectious Diseases, 2016, Vol 3, Issue 1, p1
- ISSN
2328-8957
- Publication type
Article
- DOI
10.1093/ofid/ofv201